December 21, 2020
The Pharmaceuticals and Medical Devices Agency (PMDA) is investigating new side effect risks for two cancer drugs Pomalyst (pomalidomide) and MabCampath (alemtuzumab) by Celgene and Sanofi, a move likely to trigger label changes in the near future. According to the...read more